Group 1 - The company will hold its second extraordinary general meeting of shareholders on November 25, 2025, to discuss additional proposals [1][3] - Zhejiang International Trade Group Co., Ltd., the controlling shareholder, proposed to add a temporary proposal regarding the loan limit to the company's subsidiary [2][19] - The proposal has been approved by the independent directors and the board of directors, and it complies with relevant laws and regulations [2][19] Group 2 - The loan amount proposed is 1.3 billion yuan, intended for daily operations and debt replacement, with a validity period until July 20, 2026 [13][19] - The loan interest rate will not exceed 3.15% and will be subject to the weighted average interest rate of bank loans at the time of borrowing [13][19] - The board meeting on November 13, 2025, approved the proposal with a unanimous vote, excluding the related director from voting [42][43] Group 3 - The company is also establishing the "Oriental Zheyao Zhongying Binjiang Medical Fund" with a target size of 500 million yuan, involving several partners [21][22] - The fund will focus on supporting the biopharmaceutical and medical device industries, with a management fee of 0.75% per year during the investment period [31][38] - The fund's investment strategy includes a cap on single investments and a focus on mid to late-stage projects [33][38]

格隆汇11月13日｜浙江东方公告称，公司十届董事会二十一次会议审议通过两项议案。一是同意全资子 公司东方产融联合关联方等发起设立"东方浙药中瀛滨江医药扶摇基金"，基金募资不超5亿元。东方产 融作为管理人，其及指定子公司共认缴1.212亿元，占比24.04%，浙药集团认缴0.298亿元，占比 5.96%。二是同意控股股东向控股子公司国金融资租赁提供13亿元借款额度，用于日常经营及债务置 换，有效期至2026年7月20日，年利率不高于3.15%，借款期限不超3年，该议案需提交股东会审议。 ...

Core Viewpoint - Zhejiang Oriental announced the approval of two proposals by its tenth board of directors, focusing on the establishment of a new fund and a loan provision for operational needs [1] Group 1: Fund Establishment - The company approved the establishment of the "Oriental Zhe Pharmaceutical Zhongying Binjiang Medical Fund," with a fundraising target not exceeding 500 million yuan [1] - Oriental Chanin, as the fund manager, and its designated subsidiaries will contribute 121.2 million yuan, accounting for 24.04% of the total fund [1] - Zhe Pharmaceutical Group will contribute 29.8 million yuan, representing 5.96% of the fund [1] Group 2: Loan Provision - The company agreed to provide a loan limit of 1.3 billion yuan from its controlling shareholder to its subsidiary Guojin Financial Leasing for daily operations and debt replacement [1] - The loan has a validity period until July 20, 2026, with an annual interest rate not exceeding 3.15% [1] - The loan term will not exceed three years, and this proposal requires approval from the shareholders' meeting [1]